Login

Tag: IND promotion

IND promotion

Regulatory/FDA

Promotion of IND for Brain Cancer Treatment Prompts OPDP Enforcement Letter

Promotion of IND for Brain Cancer Treatment Prompts OPDP Enforcement Letter

Dec. 2, 2019 – In its sixth Untitled Letter of 2019, the FDA’s Office of Prescription Drug Promotion (OPDP) cited Nascent Biotech Inc. for promoting an investigational new drug (IND) as a safe and effective treatment for brain cancer on its website. This is the second enforcement letter in 2019 to address issues related to […]

Read more

Categories

Recent Posts

Tags

ACA ad tax CDER chc CMS coalition for healthcare communication conflict of interest Congress COVID-19 data privacy data privacy legislation DDMAC drug prices in DTC ads drug pricing DTC DTC advertising DTC advertising FDA FDA Commissioner FDA Draft Guidance FDA enforcement FDA social media FTC HHS Jim Potter John Kamp Jon Bigelow kamp Kate Rawson legislation litigation off-label off-label communication OPDP OPDP enforcement PhRMA privacy regulation rx data Scott Gottlieb social media sunshine act Untitled Letter Warning Letter Wayne Pines